Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 10/13/2017 2:32:27 PM - Followers: 18 - Board type: Free - Posts Today: 0



Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.


 PDF Presentation Feb 2011:



Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011



Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

AOLS (Daily)

AOLS (Weekly)


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AOLS News: Quarterly Report (10-q) 08/14/2017 05:09:19 PM
AOLS News: Quarterly Report (10-q) 05/15/2017 05:59:03 PM
#551   Smack ETRF and get those .08's outta here. $AOLS MERCURIAL 10/13/17 02:32:27 PM
#550   It's definitely got a ton of potential. $AOLS MERCURIAL 10/11/17 02:14:48 PM
#549   I see this ticker on a number of tyfoidhana 10/11/17 02:10:13 PM
#548   I see this ticker on a number of tyfoidhana 10/11/17 02:10:12 PM
#547's been quiet...too quiet. lol $AOLS MERCURIAL 10/11/17 01:25:18 PM
#546   Looking for buyout or JV !! Imho big MADDSTACKER 10/11/17 01:16:55 PM
#545   Well not exactly, but for the most part Sheep 10/11/17 11:44:22 AM
#544   Does this get approval for humans based on tyfoidhana 10/11/17 10:51:53 AM
#543   Daily and weekly charts starting to squeeze hard tyfoidhana 10/10/17 10:27:23 PM
#542   lol ,, nuke , nuke ,nuke !!!!! Bawhhaahhaaha MADDSTACKER 10/10/17 01:15:57 PM
#541   Where'd they go? Guess we'll wait on a catastrophe. MERCURIAL 10/10/17 01:14:46 PM
#540   Yep. Bring that news tomorrow and let 'em MERCURIAL 10/09/17 03:16:58 PM
#539   Nice bids MADDSTACKER 10/09/17 03:11:47 PM
#538 mick 10/08/17 01:19:21 PM
#537   Damn, we biddin' .06's? Makes me wanna grab MERCURIAL 10/06/17 09:38:27 AM
#536   Agreed let her breath I'd like to be MADDSTACKER 10/03/17 02:28:26 PM
#535   People on the ask need to back the MERCURIAL 10/03/17 02:27:37 PM
#534   Yes sir! Sometimes traders have to chase. This MERCURIAL 10/02/17 09:33:43 AM
#533   Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistic MADDSTACKER 10/02/17 08:34:14 AM
#532   Sounds like it's a needed medicine ! All MADDSTACKER 09/30/17 02:13:22 PM
#531   doris over at the aols yahoo board has Sheep 09/29/17 04:21:11 PM
#530   Let's get $AOLS back over .10 next week. MERCURIAL 09/29/17 02:36:29 PM
#529   Agreed he's been there for weeks .. smh MADDSTACKER 09/27/17 11:37:00 AM
#528   If etrade would just get off the ask MERCURIAL 09/27/17 11:36:07 AM
#527   Let's go guys , this going go bonkers MADDSTACKER 09/27/17 11:30:17 AM
#526   Agreed :) MADDSTACKER 09/26/17 05:27:03 PM
#525   We are just waiting for the right people Sheep 09/26/17 04:55:32 PM
#524   Fantastic ... MADDSTACKER 09/22/17 08:27:20 AM
#523   Aeolus Announces Presentation of Pharmacometric Analysis of Data MERCURIAL 09/22/17 08:25:49 AM
#522   Bring it $AOLS MERCURIAL 09/21/17 03:27:20 PM
#521   If E*TRADE moved off ask we fly .. MADDSTACKER 09/21/17 03:20:42 PM
#520   Getting thin up top. This could pop strong jimbob4stocks 09/21/17 12:45:57 PM
#519   Nice buys coming in ! MADDSTACKER 09/21/17 11:52:30 AM
#518   Let's get back over a dime $AOLS ready MERCURIAL 09/21/17 11:39:00 AM
#517   Yes sir MADDSTACKER 09/20/17 03:14:17 PM
#516   Nice update today. This board should checkout IPLB GM26 09/20/17 03:09:49 PM
#515   $AOLS gonna play the waiting game. :) MERCURIAL 09/20/17 03:08:23 PM
#514   Accumulation ahead of a run. jimbob4stocks 09/20/17 02:01:44 PM
#513   Don't know why we're still trading .07's right MERCURIAL 09/20/17 12:23:26 PM
#512   Nice to see let's work our way back MADDSTACKER 09/20/17 10:45:37 AM
#511   There's that bid. :) $AOLS MERCURIAL 09/20/17 10:41:50 AM
#510   Also only product in this category ..... North MADDSTACKER 09/20/17 08:54:47 AM
#509   What people have to realize is that this MERCURIAL 09/20/17 08:54:12 AM
#508 MERCURIAL 09/20/17 08:52:25 AM
#507   Agreed ..... not even going watch wake me MADDSTACKER 09/20/17 08:52:07 AM
#506   I'm not driving, AOLS is firmly in control! MERCURIAL 09/20/17 08:51:26 AM
#505   We are grateful to the National Institutes of MADDSTACKER 09/20/17 08:48:37 AM
#504   Going to dollars bro sit back enjoy the MADDSTACKER 09/20/17 08:48:03 AM
#503   News: Aeolus Announces Publication of Data Demonstrating that Adding MERCURIAL 09/20/17 08:47:25 AM
#502   yes indeed. I would love to see the Sheep 09/19/17 04:38:26 PM